Oncolytics Biotech® Releases a Letter to Shareholders – 2021 Review and 2022 Outlook

SAN DIEGO, Calif. and CALGARY, AB: SAN DIEGO, Calif. and CALGARY, AB, Jan. 11, 2022 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is providing a letter to shareholders, included below. To the Shareholders of Oncolytics Biotech, 2021 generated ground-breaking data that creates the foundation for continued success in 2022 as we build our clinical opportunities and the data required to embark on our registrational study in metastatic breast cancer. This critical data encompasses data requested by the FDA and our global pharma collaborators, data that de-risks both our registrational program and clinical studies going forward. I would like to provide a summary of our 2021 accomplishments, an update on the final pieces of our metastatic HR+/HER2- breast cancer program, and provide some commentary on several of our promising programs in other indications.
Click here to view original post